In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
Contracting schemes in medtech: Challenges and opportunities
Healthcare systems have had to adapt to evolving challenges in recent years, and in response, the pharmaceutical and biotechnology sectors have implemented...